摘要
前列腺癌是男性常见恶性肿瘤,严重危害男性健康。目前针对不同分期的前列腺癌治疗后,患者生存存在差异。早期前列腺癌生存率高,预后较好。中晚期前列腺癌生存率低,预后较差。直肠指检配合血清前列腺特异性抗原(PSA)检测是目前公认的早期前列腺癌筛查方法。然而PSA特异性差,大量前列腺癌患者被过度诊断及治疗。同时针对中晚期前列腺癌治疗也需要更可靠的方式来判断治疗效果,辅助临床决策。本文就前列腺癌诊断及治疗上具有广泛应用前景的前列腺癌生物标志物予以综述。
Prostate cancer is a common malignant tumor in men,which seriously endangers men's health.At present,in the treatment of prostate cancer in different stages,the survival of patients shows differences.The survival rate of early prostate cancer is high with better prognosis,while the survival rate of advanced prostate cancer is low,and the prognosis is poor.Digital rectal examination combined with serum PSA detection is currently recognized as the best method for early prostate cancer screen⁃ing.However,the specificity of PSA is poor,and a large number of prostate cancer patients are over⁃diagnosed and over⁃treated.At the same time,the treatment of advanced prostate cancer also needs more reliable biomarkers to judge the treatment effect and assist clinical decision⁃making.
作者
赵国臣
吴波
张彬
胡操阳
贾杰东
王东文
ZHAO Guo-chen;WU Bo;ZHANG Bin;HU Cao-yang;JIA Jie-dong;WANG Dong-wen(Department of Urology,the First Hospital of Shanxi Medical University,Taiyuan 030001,China;Department of Urology,National Cancer Center,National Cancer Clinical Research Center Shenzhen Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences and Shenzhen Hospital,Shenzhen 518116,China)
出处
《海南医学院学报》
CAS
2021年第14期1116-1120,共5页
Journal of Hainan Medical University
基金
山西省重点研发计划(201803D31110)
山西省重点研发计划(201603D321068)
山西省卫生计生委科研课题(2018045)。
关键词
前列腺癌
生物标志物
诊断
预后
Prostate cancer
Biomarkers
Diagnosis
Prognosis
